---

 

 

July 31, 2024

 

CORRESPONDENCE FILED VIA EDGAR

 

Office of Life Sciences

Division of Corporation Finance

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention: Daniel Crawford

 

Dear Mr. Crawford:

 

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Acasti Pharma Inc. (the “Company”) hereby respectfully requests that the U.S. Securities and Exchange Commission accelerate the effective date and time of the above referenced Registration Statement on Form S-4 (the “Registration Statement”) and declare the Registration Statement effective as of 4:00 p.m. Eastern Time on August 2, 2024, or as soon thereafter as practicable.

 

The Company requests that it be notified of such effectiveness by a telephone call to Steven Abrams of Hogan Lovells US LLP at (267) 675-4671.

 

[Signature page follows]

 

 

 

---